2007 Archive
Accera Inc. announced today that the company will be participating in the Rodman & Renshaw 9th Annual Healthcare Conference November 5-7 at the Palace Hotel in New York City. President and CEO Dr. Steve Orndorff will present the company November 7 at 12:40 p.m. in the Hubbard Room.
Accera, Inc. has appointed William T. Poncy, M.B.A., as Vice President of Commercial Development. He will direct the commercial launch of Ketasyn (AC-1202) as a medical food product in the U.S. for the treatment of Alzheimers' disease and the development of the ethical drug franchise for neurodegenerative diseases at Accera.
Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, announced today that the company will be participating in the 4th Annual BIO Investor Forum next week at the Palace Hotel in San Francisco
A double-blind, placebo-controlled Phase II study with 159 subjects characterized with Age-Associated Memory Impairment showed that Ketasyn (AC-1202) has a positive and clinically meaningful effect on memory in older adults. The study results were consistent with earlier Phase II studies done with Alzheimer's disease patients, particularly those with the APOE4(-) genotype who showed significant improvement in memory and cognition.
Accera, Inc. announced today that recent data from its Phase IIb study in Alzheimer's disease (AD) support findings showing that AD may effectively be thought of and treated as diabetes of the brain.
All subjects who were treated with AC-1202 during the full nine months of the double-blinded and open-label phases of the clinical trial showed very little disease progression. Patients with the ApoE4(-) genotype who started taking AC-1202 for the first time during the open-label extension showed significant improvement in memory and cognition. This result was consistent with the double-blinded phase of this study as well as an earlier Phase IIa clinical study.
Accera, Inc. announced today that the company will participate in three upcoming healthcare investor conferences, Dr. Steve Orndorff, President and CEO, will make presentations about the business of the company, its technology platform and the recent positive data from a Phase IIb study of AC-1202 for Alzheimer's disease.
Accera announced the topline results of a Phase IIb clinical study of its lead compound, AC-1202, in 152 patients diagnosed with mild-to-moderate Alzheimer's disease. The multi-center trial, conducted in the U.S., was designed as a double-blinded, placebo-controlled study over 104 days, followed by a six month open-label extension phase. Signficant efficacy was observed in those patients treated with AC-1202, particularly in those with the ApoE4(-) genotype and one other pharmacogenomic marker that is involved in brain energy metabolism.
Accera announced today that the topline data from its Phase IIb study of its lead compound, AC-1202, in Alzheimer's disease will be presented at the annual meeting of the American Academy of Neurology in Boston by Dr. Lauren Costantini, Vice President of Clinical Development.
Accera executive management participated in a public policy tour with the Neurotechnology Industry Organization (NIO) that met with the FDA, NIH and elected members of Congress to discuss opportunities and obstacles facing companies in the development of new therapies for diseases of the central nervous system. During the tour NIO promoted the concept of a National Neurotechnology Initiative with a federal National Coordination Office to direct existing multi-agency efforts in neurotechnology. Accera is a founding member of NIO.
Accera, Inc. announced today an agreement under which it has granted Nestle Purina PetCare Global Resources, Inc. the right to develop its proprietary compound, AC-1203, for application to healthy aging and wellness in dogs and other companion animals.
Want to read more? Please visit our news archives pages.